Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Introduction to Hemostasis01:05

Introduction to Hemostasis

Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized, and...
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Renoir phase III Rituximab-Lenalidomide vs Rituximab as Maintenance Treatment in Relapsed/Refractory Follicular Lymphoma.

Blood advances·2026
Same author

Outcomes of CAR T-Cell Therapy in transformed indolent Non-Hodgkin Lymphomas and de novo DLBCL: A comparative analysis from the Italian CAR T-SIE study.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Daratumumab in combination with GDP chemotherapy in CD38-positive relapsed/refractory peripheral T-cell lymphoma: a phase 2 study of the Fondazione Italiana Linfomi.

Annals of hematology·2026
Same author

Dissecting minimal residual disease dynamics to improve outcome prediction in mantle cell lymphoma: Data from the Fondazione Italiana Linfomi (FIL)-MCL0208 clinical trial.

HemaSphere·2026
Same author

Tumor microenvironment remodeling by STING agonism sensitizes endothelial cells to cytotoxic anti-PD-L1/L2 antibody.

Journal of experimental & clinical cancer research : CR·2026
Same author

Quantitative MYD88 L265P and flow cytometry levels for outcome determination in IgM gammopathies: the SAL-TO study.

Blood advances·2026

Related Experiment Video

Updated: Jul 2, 2026

Venous Thrombosis Assay in a Mouse Model of Cancer
04:40

Venous Thrombosis Assay in a Mouse Model of Cancer

Published on: January 5, 2024

The hemostatic system and malignancy.

Dorothy M Adcock1, Louis M Fink, Richard A Marlar

  • 1Esoterix, Inc. Aurora, Colorado, USA.

Clinical Lymphoma & Myeloma
|September 4, 2008
PubMed
Summary
This summary is machine-generated.

Malignancy and hemostasis (blood clotting) are closely linked. This review explores how blood clotting affects cancer growth, spread, and how anticoagulants impact patient survival.

Related Experiment Videos

Last Updated: Jul 2, 2026

Venous Thrombosis Assay in a Mouse Model of Cancer
04:40

Venous Thrombosis Assay in a Mouse Model of Cancer

Published on: January 5, 2024

Area of Science:

  • Oncology
  • Hematology
  • Cancer Biology

Background:

  • Malignancy and hemostasis share intricate connections.
  • Cancer cells can activate blood clotting pathways.
  • The hemostatic system may influence tumor progression.

Purpose of the Study:

  • To review mechanisms by which malignancy promotes thrombosis.
  • To emphasize how the hemostatic system modulates tumor potential.
  • To present thrombotic and nonthrombotic processes enhancing tumor growth, angiogenesis, and metastasis.

Main Methods:

  • Literature review of existing research on malignancy and hemostasis.
  • Analysis of mechanisms linking coagulation and cancer.
  • Examination of anticoagulant effects on cancer patient survival.

Main Results:

  • Malignancy actively promotes thrombosis through various mechanisms.
  • Hemostasis influences tumor growth, angiogenesis, and metastasis.
  • Anticoagulants (e.g., vitamin K antagonists, heparin) show effects on cancer patient survival.

Conclusions:

  • The interplay between coagulation and tumor biology is a dynamic field.
  • Further research into these interactions may yield clinical breakthroughs.
  • Development of novel anticoagulants and cancer therapies is ongoing.